Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Restructuring Costs (2022 - 2025)

Marimed has reported Restructuring Costs over the past 4 years, most recently at $90000.0 for Q4 2025.

  • Quarterly Restructuring Costs fell 38.36% to $90000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $486000.0 through Dec 2025, down 48.9% year-over-year, with the annual reading at $486000.0 for FY2025, 48.9% down from the prior year.
  • Restructuring Costs was $90000.0 for Q4 2025 at Marimed, down from $145000.0 in the prior quarter.
  • Over five years, Restructuring Costs peaked at $754000.0 in Q2 2022 and troughed at $32000.0 in Q3 2023.
  • The 4-year median for Restructuring Costs is $143000.0 (2022), against an average of $206200.0.
  • Year-over-year, Restructuring Costs plummeted 77.62% in 2023 and then soared 1059.38% in 2024.
  • A 4-year view of Restructuring Costs shows it stood at $64000.0 in 2022, then fell by 25.0% to $48000.0 in 2023, then skyrocketed by 204.17% to $146000.0 in 2024, then crashed by 38.36% to $90000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Restructuring Costs are $90000.0 (Q4 2025), $145000.0 (Q3 2025), and $139000.0 (Q2 2025).